Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 5/20 | 0.57 |
| ▸ | EGFR | P00533 | 4/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.57 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 4/20 | 0.53 |
| ▸ | ZAP70 | P43403 | 4/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.53 |
| ▸ | PRKCG | P05129 | 3/20 | 0.53 |
| ▸ | PRKCB | P05771 | 3/20 | 0.53 |
| ▸ | PRKCA | P17252 | 3/20 | 0.53 |
| ▸ | PRKCH | P24723 | 3/20 | 0.53 |
| ▸ | PRKCI | P41743 | 3/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3254607 | 0.89 | PIK3CA (0.61) | RETCDK2EGFRJAK2PIK3CA | |
| SCHEMBL3255561 | 0.87 | CDK2 (0.61) | RETCDK2EGFRJAK2PIK3CA | |
| SCHEMBL3252211 | 0.87 | CDK2 (0.73) | RETCDK2EGFRJAK2PIK3CA | |
| SCHEMBL3258028 | 0.85 | RET (0.58) | RETCDK2EGFRJAK2PIK3CA | |
| SCHEMBL3250543 | 0.81 | CDK2 (0.55) | RETCDK2EGFRJAK2PIK3CA | |
| SCHEMBL3254612 | 0.79 | CLK1 (0.53) | RETCDK2EGFRJAK2PIK3CA | |
| SCHEMBL3255217 | 0.77 | PIK3CA (0.58) | RETCDK2EGFRJAK2PIK3CA | |
| SCHEMBL4362670 | 0.77 | RET (0.68) | RETCDK2EGFRJAK2PIK3CA | |
| SCHEMBL3256174 | 0.76 | CDK2 (0.48) | RETCDK2EGFRJAK2PIK3CA | |
| SCHEMBL6979315 | 0.76 | CDK2 (0.79) | RETCDK2EGFRJAK2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521749-B8 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-22 | — | — | EP | claimed |
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | FURET PASCAL | 2006-05-18 | — | — | US | claimed |
| EP-1521749-A1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | Novartis AG (CH) | 2005-04-13 | — | — | EP | claimed |
| WO-2004005282-A1 | PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | claimed |
| EP-1521749-B1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| US-7691855-B2 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | FURET PASCAL | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | MKI67, CCNI, PAH | RET 1252/4885CDK2 22/4885EGFR 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.